Results 231 to 240 of about 207,197 (306)

Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. [PDF]

Nat Commun
Rudman Spergel AK, Lee IT, Koslovsky K, Schaefers K, Avanesov A, Logan DK, Hemmersmeier J, Ensz D, Stadlbauer D, Hu B, Pucci A, Vakil J, Paris R, Ananworanich J, Nachbagauer R.   +14 more
europepmc   +1 more source

Assessment of sampling variation applets during development

Teaching Statistics, Volume 48, Issue S1, Page S97-S121, Summer 2026.
Abstract Concepts relating to sampling variation are known to be difficult for learners in introductory classes. There is some evidence that web‐based visualization tools, or “applets,” may aid the learning of these challenging ideas. Four freely available applets developed at the authors' institution were extensively tested through sessions involving ...
Bruce Dunham, Nancy Heckman, Melissa Lee, Mike Whitlock, Gaitri Yapa   +4 more
wiley   +1 more source

Evaluating Bacillus Calmette-Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice. [PDF]

Influenza Other Respir Viruses
Yan S, Yang F, Ji J, Lin X, Wang P, Wu H, Cheng L, Liu F, Wu N, Yao H, Wu WSJ, Wu H.   +11 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Research Priorities for Zoonotic and Pandemic Influenza Vaccines: Evidence and Recommendations from the WHO Public Health Research Agenda for Influenza (2024 Update). [PDF]

Vaccines (Basel)
Zhang W, Cowling BJ, Tam JSL, Abraham T, Chen H, Duggal K, Khong WX, Maurer-Stroh S, Monto AS, Nikisins S, de Oliveira T, Shu Y, Viboud C, Webby R, van der Werf S, Wong J, Heraud JM.   +16 more
europepmc   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis. [PDF]

Front Pharmacol
Wei Z, Yu S.
europepmc   +1 more source

Pharmacy‐Based Immunization Delivery: A Comprehensive History and Current Challenges

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 6, June 2026.
ABSTRACT Pharmacists and their teams have a long history of involvement with vaccines. This paper describes the contributions of pharmacy‐based immunization delivery in the United States from the 1800's to date. Early activities centered around storage and distribution of antitoxins and vaccines. From the 1950s through the early 1990s, pharmacists were
Jean‐Venable R. Goode, Mitchel C. Rothholz, Stephan L. Foster, Erica R. Brody, John D. Gräbenstein   +4 more
wiley   +1 more source

IAPSM's Position Paper on Influenza Vaccines for Adult Immunization in India. [PDF]

Indian J Community Med
Sharma N, Verma M, Goel K, Kulkarni MM, Bhardwaj A, Sharma S, Singh T, Gupta M, Nadda A, Sankhe LR.   +9 more
europepmc   +1 more source

Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq, Doni Dermawan, Samir Chtita   +2 more
wiley   +1 more source